Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.58 |
| ▸ | PER2 | O15055 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9024455 | 0.76 | CHRM2 (0.67) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9031196 | 0.76 | CHRM2 (0.67) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11728856 | 0.74 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8840323 | 0.74 | CHRM2 (0.94) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9029692 | 0.72 | CHRM2 (0.78) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3924220 | 0.71 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11731840 | 0.71 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9030017 | 0.68 | CHRM2 (0.58) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11724996 | 0.68 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL11724991 | 0.67 | CHRM2 (0.68) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1994023719-A1 | OPHTHALMIC USE OF MUSCARINIC AGONISTS HAVING INCREASED DURATION OF ACTIVITY | ALLERGAN, INC. (US) | 1994-10-27 | — | — | WO | claimed |
| US-5677327-A | MEASURING THE AGONIST ACTIVITY OF THE COMPOUND AT M3 AND M5 MUSCARINIC RECEPTORS AND DETERMINING FROM SAID ACTIVITY THAT THE COMPOUND WHICH HAS ATLEAST TWICE THE AGONIST ACTIVITY AT M5 RECEPTOR AS COMPARED TO M3 RECEPTOR IS SUITABLE AGONIST | ALLERGAN (US) | 1997-10-14 | — | — | US | disclosed |
| US-5521210-A | Ophthalmic use of muscarinic agonists having increased duration of activity | ALLERGAN, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| WO-1994023719-A1 | OPHTHALMIC USE OF MUSCARINIC AGONISTS HAVING INCREASED DURATION OF ACTIVITY | ALLERGAN, INC. (US) | 1994-10-27 | — | — | WO | disclosed |